The Study Evaluates the Safety and Renal Sparing Efficacy of Lixudebart Basel, Switzerland – Dec 5, 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the first patient dosed in a Phase 2 clinical trial of lixudebart (formerly named ALE.F02), a Claudin-1 (CLDN1) targeting investigational antibody for the treatment of organ fibrosis.The randomized, double-blind, placebo-controlled Phase 2 study (NCT06047171) of lixudebart evaluates the drug’s safety, tolerability, pharmacokinetics, and how well it protects against the loss of kidney function. The study plans to recruit patients with Antineutrophil Cytoplasmic Antibody…

This First-in-Human Study Evaluates the Safety, Tolerability and Efficacy of ALE.C04 as a Monotherapy and in Combination Basel, Switzerland – Nov 16, 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that the first patient has been dosed in a Phase 1/2 clinical trial of ALE.C04, a Claudin-1 (CLDN1) targeting investigational antibody for the treatment of CLDN1+ tumors. The patient is enrolled under the Phase I program, led by Anthony El-Khoueiry, MD, Associate Director of Clinical Research, at University of Southern California (USC) Norris Comprehensive Cancer Center, part…

Planned Attendance at Bio Europe, LSX Inv€$tival Showcase, Jefferies Healthcare and Piper Sandler Healthcare Conferences Basel, Switzerland – Nov 2, 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today participation in four business conferences during the Month of November including company presentations at the LSX Inv€$tival Showcase in London, UK and the Piper Sandler Annual Healthcare Conference in New York, NY.Bio EuropeAlentis will take part in the conference November 6–8, 2023 at the Messe München, Munich, Germany.LSX Inv€$tival ShowcaseRoberto Iacone, CEO of Alentis will give a company presentation…

Poster Presentation on ALE.F02 as Potential Treatment for Kidney Fibrosis Basel, Switzerland – 26 Oct 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today a poster presentation on the first day of the American Society of Nephrology (ASN) Kidney Week being held November 2-5, 2023, in Philadelphia, PA, USA. Poster details Title: Claudin-1 is a therapeutic target for crescentic glomerulonephritis (Abstract TH-PO531) Presenter: Geoffrey Teixeira, SVP Head of Fibrosis, Alentis Therapeutics Session: Glomerular Diseases: From Inflammation to Fibrosis (1401) Date and time: Thursday, November 2, from 10:00 am…

Basel, Switzerland – 5 Oct 2023, Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong and Steven Nathan, Professor at the University of Virginia as members of its Scientific Advisory Board. “Tony and Steven have exceptional expertise in lung cancer and lung fibrosis, respectively, which will be of great value to our Scientific Advisory Board,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis. “Their input will be key for Alentis as we…

Basel, Switzerland – 20 Sept 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today it is a proud sponsor of the 5th Vasculitis Training Course organized by the European Vasculitis Society (EUVAS) being held 28-30 September in St Gallen, Switzerland. “We are pleased to have Alentis as one of the sponsors for the EUVAS Vasculitis Training Course”, said Dr. David Jayne, co-founder and the current President of EUVAS. “With the training course we aim to provide medical education on vasculitis to physicians, researchers and others interested in vasculitis.”…

Basel, Switzerland – 6 September 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today two company presentations at investor conferences in September and October. UBS Biotechnology Private Company Virtual Symposium The virtual conference is to be held September 20-21, 2023. Roberto Iacone, Chief Executive Officer of Alentis will participate in a fireside chat on Thursday, September 21 at 8:30 am ET. Oppenheimer Private Healthcare Company Showcase The conference is to be held October 11, 2023 at The Intercontinental New York Barclay Hotel. Roberto Iacone will give a company…

Late-Breaking Oral Presentation on ALE.F02 as Potential Treatment for Pulmonary Fibrosis Basel, Switzerland – 29 August 2023, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today an oral presentation during the ERS International Congress to be held September 9-13 in Milan, Italy.Presentation detailsTitle: Claudin-1 is a potential airway-centric therapeutic​ target for pulmonary fibrosis​ (Abstract OA2623)Presenter: Geoffrey Teixeira, SVP Head of Fibrosis, Alentis TherapeuticsSession: #271 - Innovations in pulmonologyDate and time: Monday, 11th September 2023, 11:00 CET“ALE.F02 is being developed to stop progression or reverse organ fibrosis by specifically targeting…

The Study Evaluates the Pharmacokinetics of ALE.F02 in Advanced Liver Fibrosis Patients Basel, Switzerland – 13 July 2023,  Alentis  Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that the first patient with liver fibrosis has been dosed in the Phase 1b “FEGATO-01” clinical trial of ALE.F02, a CLDN1 targeting investigational antibody for the treatment of liver, kidney, and lung fibrosis. “ALE.F02 can potentially reverse advanced liver fibrosis,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis. “We have a truly differentiated approach of inhibiting pathologically overexpressed CLDN1 to transform…

Santarelli is a Proven Leader with a Track Record of Building Successful Biotech Companies Basel, Switzerland – 29 June 2023,  Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Dr. Luca Santarelli as the Chair of its Board of Directors. Rafaèle Tordjman, former chair of Alentis, will remain on Alentis’ board. “I’m pleased to welcome Luca as Chair of our board. His experience as a serial biotech entrepreneur and Alentis board member since 2021 are of great value to our board and company,” said Dr. Roberto…